



P R E S S R E L E A S E

April 2, 2007
Joachim Weith, Corporate Communications
Tel.: +49 - 6172 - 6082101
Fax: +49 - 6172 - 6082294
e-mail: pr-fre@fresenius.de
www.fresenius-ag.com

Fresenius ProServe completes the divestiture of Pharmaplan GmbH

Fresenius ProServe closed the announced divestiture of its subsidiary Pharmaplan GmbH to NNE A/S on March 31, 2007. All necessary antitrust approvals were received by NNE prior to the completion of the acquisition.

NNE is a wholly-owned subsidiary of Novo Nordisk A/S, Copenhagen, a pharmaceutical company with approximately 23,200 employees worldwide and annual sales of €5,194 million in 2006.

Pharmaplan provides consulting, engineering and qualification/validation services for the pharmaceutical industry worldwide. The sale of Pharmaplan is a further step by Fresenius ProServe to focus on its two core areas hospital operations (HELIOS Kliniken) and hospital engineering and services (VAMED).

###

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and the ambulatory medical care of patients. In 2006 group sales were about €10.8 billion. On December 31, 2006 the Fresenius Group had 104,872 employees worldwide.

For more information visit the Company's website at www.fresenius-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.